Antonio Siccardi 2004, Swimming Anita Antonio G. Siccardi - 18 marzo 2010 Edward Jenner, 1798, An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Known by the Name of Cow Pox La Vaccinazione di Jenner non era che una forma meno pericolosa della Variolazione (che poteva causare il vaiolo in alcuni pazienti), ma il vignettista satirico ne proponeva una interpretazione letterale (crescite di protuberanze con sembianze bovine nei soggetti vaccinati) The wonderful effects of the new inoculation! Publications of the Anti-Vaccine Society published June 12, 1802 by H. Humphrey, St. James's Street. 2009: niente di nuovo sotto il sole! La “società anti-vaccino è più agguerrita che mai “suinazione” Comunque, … 1796-1979 Eradicazione del vaiolo L’unica malattia umana che sia mai stata eradicata! Solo 4 Poxvirus infettano l’uomo: Variola (>>>Vaiolo) Cowpox Vaccini anti-vaiolo Vaccinia Monkeypox 350 nm Come unico virus attenuato che abbia eradicato una malattia umana, il virus vaccinia è il miglior candidato di vettore biotecnologico per nuovi vaccini ricombinanti che inducano immunità contro qualunque immunogeno (e.g. virale o tumorale) espresso da un transgene ingegnerizzato nel genoma del vettore transgene ds DNA lineare ca. 200 kb (estremità ripetitive, richiuse ad anello) 270 nm < Troppo virus < Limiting dilution < No No virus virus Il virus Vaccinia è facile da maneggiare (in colture cellulari) L’inserimento (distruttivo) nel gene TK causa il fenotipo TK- (resistenza al BUdR). gene TK attivo vaccinia sequenze di TK plasmide transgene con promotore di vaccinia vaccinia gene TK inattivato Vaccinia virus was introduced as a vector for transient gene expression in mammalian cells in 1982 (Mackett, 1982; Panicali and Paoletti, 1982) • Wide host range • High level expression of the transgene • The expression does not require nuclear processing and RNA transport • “Appropriate” transport, secretion, processing and post-translational modifications (N-, O-glycosilation, phosphorylation, myristilation, cleavage, assembly) • Protection afforded by immunization can be correlated with neutralizing antibodies and/or induction of CTLs Complications / Adverse Reactions From Traditional Smallpox Vaccine Inadvertent Inoculation Generalized Vaccinia Eczema Vaccinatum Progressive Vaccinia Erythema Multiforme MVA Modified Vaccinia Virus Ankara (Anton Mayer, Monaco) Più di 500 passaggi su fibroblasti di embrione di pollo. Sei delezioni maggiori (208>>>177 kBp). Non replica più su cellule di mammifero (ad eccezione delle cellule BHK-21). (Il gene K1-L permette la crescita anche su RK-13) Complications / Adverse Reactions MVA None! Argomenti del Seminario di oggi: • Nuovi metodi per produrre Poxvirus ricombinanti • Prospettive di un vaccino ricombinante “universale” contro l’influenza The “poxvirus vector” team in Milano, San Raffaele Scientific Institute. Maddalena Panigada Elisa Soprana Giulia Di Lullo Luisa Vigevani Alessio Palini 100 nm (Modified vaccinia virus Ankara and Fowlpox Virus) are poxviruses widely employed as experimental and human live vaccine vectors for their: 1. lack of replication in mammalian cells 2. high expression of heterologous genes • MVA and FPV are not cross-reactive, therefore recombinants expressing the same immunogen can be used in sequence (prime/boost strategies). (DNA/AAV) MVA FPV IR/Protection Recombinant selection is performed by introducing the transgene within a cassette that contains VV-gene K1L, which allows growth in cell line RK-13. Red-to-green gene swapping is functional for screening green recombinants which did not carry-over red parental virus J Virol Methods. 2009; 156:37-43. PMID: 19038289 Recombinant selection is performed by FACS Red-to-green gene swapping is functional for both selecting and screening green recombinants that do not carry-over red parental virus J Virol Methods. 2009 Sep 22. [Epub ahead of print] PMID: 19778556 Infection / Transfection ca. 1:1000 CEF monolayer I/T lysate MVA-Red Single-cycle infection sP flank 2 flank 1 HcRed1-1 Z Z P egfp TG P7.5 Tranfer Plasmid-Green Single cell sorting rMVA production in SF-CEF cultures CEF monolayer BHK-21 + I/T lysate (1:100) single green cells sorted onto monolayers i.e. the green cells are covered with “red” virions single green cells sorted onto monolayers +IMCBH The inhibitor of Golgi wrapping IMCBH allows to sort individually infected cells with no carry-over of newly shed viruses IMCBH (Schmutz et al., 1991) (N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine) Reversible Inhibitors of Vaccinia Virus release IMCBH Cytochalasin D 1. 2. 3. 4. Infection /transfection in CEF Collect lysate Infect CEF Flow analysis at 8, 24, 48 h HA/Green Red/HA Green/HA A EGFP TG Z B Z 3rd Recombination in Z A TG Z B Terminal Dilution cloning of marker-free segregants Staining Typhoon Fluoroimaging rMVA and rFPV expressing the same transgene allow to perform prime/boost (or DNA prime/MVA boost/FPV boost) vaccination regimens, avoiding the problem of neutralizing antiviral responses Parallel production of rMVA and rFPV HcRed1-1 HcRed1-1 sP Construction of the “acceptor” viral vector sP MVA flank 1 MVA flank 2 pMVA Transfer Plasmid HcRed1-1 MVA flank 1 MVA flank 2 pFPV Transfer Plasmid FPV FP flank 1 which contains the two MVA homology regions flanking the red reporter gene FP flank 2 HcRed1-1 MVA flank 1 FPV RED/DUAL sP MVA flank 2 I/T FACS sorting FPV RED/DUAL HcRed1-1 FP flank 1 FP flank 2 sP MVA flank 1 MVA flank 2 MVA Transfer Plasmid With TG-Green Cassette FPV RED/DUAL FP flank 1 FP flank 2 TRANSGENE MVA flank 1 The Virus FPV RED/DUAL is used as acceptor of MVA Transfer Plasmid-Green Cassettes MVA flank 2 Soprana rFPV FPV-RED-DUAL rMVA sP flank 2 flank 1 MVA-RED HcRed1-1 Z HcRed1-1 Z Z P egfp sP flank 2 flank 1 TG Z P P7.5 Tranfer Plasmid-Green egfp TG P7.5 Tranfer Plasmid-Green The same transfer construct is used to produce “parallel” rMVA and rFPV Infection / Transfection Sorting FACS Cloning Terminal Dilution Imaging Typhoon Construction of recombinant poxviruses expressing Avian Influenza immunogens orthomyxovirus poxvirus A possible advantage of poxvirus vs. influenza vaccines Influenza vaccine yields (H5N1 & H1N1)* : about 1.4 doses per egg. rMVA vaccines are also produced from egg-derived CEF. **Virus yields on SF-CEF range around 5x1010 pfu/egg. ***Vaccination doses range around 5x107 pfu/dose. rMVA Vaccine yields: about 103 doses per egg. ________________________________________________ *Dr. Robin Robinson, director of HHS's Biomedical Advanced Research and Development Authority (BARDA) **Our own (conservative) estimates. ***Combination Study With MVA BN and Dryvax (Bavarian Nordic) Influenza Vaccines Aiming at a “universal vaccine” Collaborations: Reinhard Kurth, Steve Norley, Isaac Sipo, Mathias Knauf. Robert Koch Institut, Berlin Targets: NP, M1, M2 (conserved antigens). -Ilaria Capua, Maria Serena Beato, Adelaide Milani. Istituto Zooprofilattico 3 Venezie, Legnaro, Padova -Elisa Vicenzi, Anna Kajaste. Dibit, Milano -Antonio Lanzavecchia, Davide Corti. IRB, Bellinzona Targets: HA (conserved epitopes). M1-V5 (267Aa, 29kDa) = MSLLTEVETYVLSIIPSGPLKAEIAQKLEDVFAGKNTDLEALMEWLKTRP ILSPLTKGILGFVFTLTVPSERGLQRRRFVQNALNGNGDPNNMDRAVKLY KKLKREITFHGAKEVALSYSTGALASCMGLIYNRMGTVTTEVAFGLVCAT CEQIADSQHRSHRQMATITNPLIRHENRMVLASTTAKAMEQMAGSSEQAA EAMEIANQARQMVQAMRTIGTHPNSSAGLRDNLLENLQAYQKRMGVQMQR FKMDDLGSIPNPLLGLD M2-V5 (112Aa, 13kDa) = MSLLTEVETPTRNEWECRCSDSSDPIVVAANIIGILHLILWILDRLFFKC IYRRLKYGLKRGPATAGVPESMREEYRQEQQSAVDVDDGHFVNIELEMDD LGSIPNPLLGLD NP NP-V5 (513Aa, 58kDa) = MASQGTKRSYEQMETGGERQNATEIRASVGRMVSGIGRFYIQMCTELKLS DYEGRLIQNSITIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYRRR DGKWVRELILYDKEEIRRIWRQANNGEDATAGLTHLMIWHSNLNDATYQR TRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGTMVMELIRMIKRG INDRNFWRGENGRRTRIAYERMCNILKGKFQTAAQRAMMDQVRESRNPGN AEIEDLIFLARSALILRGSVAHKSCLPACVYGLAVASGYDFEREGYSLVG IDPFRLLQNSQVFSLIRPNENPAHKSQLVWMACHSAAFEDLRVSSFIRGT RVVPRGQLSTRGVQIASNENMEAMDSNTLELRSRYWAIRTRSGGNTNQQR ASAGQISVQPTFSVQRNLPFERATIMAAFTGNTEGRTSDMRTEIIRMMES ARPEDVSFQGRGVFELSDEKATNPIVPSFDMNNEGSYFFGDNAEEYDNMD DLGSIPNPLLGLD IPA & WB analysis (anti-V5 mAb-HRP) rMVA-M2 rMVA-NP NP M1 45 220 31 97 21 14 29 kDa 66 45 58 kDa Pandemic strain A/H1N1/09 (swine) Obtained: coHA, coM1, coNP sequences from RKI Constructed: rMVA-coHA, rMVA-coM1, rMVA-coNP - + coH1 A2-7 - + coNP 2B - - 98 - 64 - 50 - 36 + coM1 6-5 -- 64 50 36 22 16 - 22 WB anti H1N1 Primary Ab: Chicken anti-H1N1 antiserum Secundary Ab: HRP-rabbit anti-chicken Ig Soprana & Panigada Prime/boost vaccination regimens rDNA (or rAAV) /rMVA rMVA /rFPV rDNA (or rAAV) /rMVA /rFPV for transgenes M1, M2, NP, are tested at RKI, Berlin Preliminary results indicate NP as the best immunogen (in rDNA format), M1 is also a good immunogen (in rAAV format) HA-Adelaide has been derived from an H5N1 isolate from a migrant swan dead in HPAIV A/cygnus Sicily olor/Italy/724/2005 HA-Cygnus vs.HA-Vietnam Loop 130 Helix 190 Loop 220 MVA-HA Cygnus HA expression IPP foci on BHK-21 Primary CEF were infected O/N with MVA-HA, or MVA-RED. Trypsinized, mixed with ChRBC, spun into a pellet, resuspended and spun through Histopaque. The red pellets from MVA-HA infected CEF contained rosettes CEF + MVA-HA (20) HA is expressed on the surface of infected cells in a functional form and binds to sialic acid on the surface of ChRBC forming ROSETTES CEF + MVA-HA (10) CEF + MVA-RED MVA Vaccination/Homologous Challenge Experiment rMVA vaccination of chicken dose: 1e8 pfu sc (single shot) Survival: vaccinated controls 10/11 0/10 !!!!! Chicken vaccinated with rMVA-H5 and challenged with 1e5 EID50 of HPAIV A/cygnus olor/Italy/724/2005 PCR cycles: neg>35 Day Post Infection Chicken N° 31 32 33 34 35 36 37 38 39 40 SN 41 CS: cloacal swab TS: tracheal swab Neg: Negative 3 CS Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 5 TS 34.1 29.6 29.7 34.6 Neg Neg 30.2 32 33.7 34.1 31.6 CS Neg Neg Dead Neg Neg Neg Neg Neg Neg 34 Neg 7 TS 34 30.6 Dead 34.2 34.7 Neg Neg Neg Neg Neg 32.1 CS 32.9 Neg Dead Neg Neg Neg Neg Neg Neg 22.0 Neg 10 TS Neg 34.7 Dead Neg Neg 34.6 Neg 34.9 Neg Neg 34.8 CS Neg Neg Dead Neg Neg Neg Neg 32 34.6 Neg Neg TS Neg Neg Dead Neg Neg Neg Neg Neg Neg Neg Neg All the animals were infected, but only one died: virus was found and subsequently cleared in trachea and cloaca Haemagglutination inhibition assay (HI) The HI titer shoots up after infection Conventional flu vaccines reach HI = 7 pre-challenge MVA Vaccination/Heterologous Challenge Experiment 0 bleed 1st bleed 1st immunisation 2nd bleed and transfer to L3 2nd immunisation Immunisaton with 107 pfu: MVA-HA-Cygnus MVA-NP-VN MVA-M1-VN MVA-M2-VN Mix of all 4 antigens Controls: MVA empty vector Mock (PBS) H5N1 challenge (10 LD50) A/VN1203 Immunisation: twice at 0 and 3 weeks Blood sample: before and after immunisation Weighing and observation: 14 d Experiment performed by Ilia Semmler, RKI, P15 110 105 100 95 90 85 80 Empty Vector MVA-HA MVA-NP MVA-M1 MVA-M2 MVA-HA,NP,M1,M2 75 Weight (%) 105 100 95 90 85 80 75 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 105 100 Weight kinetics for 14 d after challenge 95 90 85 80 PBS 75 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Days post challenge 3d post challenge, 1-2 mice/group were sacrificed for viral load measurement in lungs 105 104 Immunogen Mock/PBS MVA-mix MVA-mix MVA-M2 MVA-M1 MVA-NP MVA-NP MVA-HA 102 MVA-HA 103 Empty Vector Viral Load (Pfu/g Lung) 106 Heterologous protection implies that Abs are made against neutralizable heterosubtypic epitopes (outside the globular head) Headless Haemagglutinin Mab C179 >> Sagawa H et al.The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol. 77:1483-7, 1996. Effect of vaccination with CV-1 cells transformed with pENH2dHO1 (=headless HA), against heterologous challenge with A/FM/1/47 (H1 N1), in mice. Heterologous challenge headless HA protection heath-treated headless HA wt HA no protection Sagawa H et al.The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol. 77:1483-7, 1996. Heterosubtypic Human Monoclonal antibodies do exist! rMVA-HA (H1swine & H5 swan) display cross-reactive epitopes on the surface of infected cells NC SC-H5 FLD194 Key Key Key Key Key Name 27.11.09.007 Gate G1 G1 27.11.09.014 FL1-H G1 27.11.09.017 FL1-H G1 27.11.09.024 FL1-H G1 27.11.09.027 27.11.09.031 FL1-H G1 27.11.09.034 FL1-H G1 27.11.09.037 Name 27.11.09.002 Parameter FL2-H Gate G1 Name 27.11.09.005 Parameter FL1-H Gate G1 27.11.09.015 FL1-H G1 27.11.09.012 FL2-H G1 27.11.09.025 FL1-H G1 27.11.09.022 FL2-H G1 27.11.09.035 FL1-H G1 27.11.09.032 FL2-H G1 Name Name 27.11.09.003 27.11.09.010 Parameter Parameter FL1-H FL1-H Gate Gate G1G1 27.11.09.013 27.11.09.020 FL1-H FL1-H G1G1 27.11.09.023 FL1-H G1 27.11.09.033 FL1-H G1 Gate G1 27.11.09.011 FL1-H 27.11.09.021 27.11.09.040 FL1-H FL1-H FG20 FLA3 G1 G1 Key FE17 Parameter FL1-H Parameter FL1-H 27.11.09.030 CEF uninfected CEF-MVA-H5 CEF-MVA-H1 CEF-MVA-IgE FE43 Name 27.11.09.004 Name 27.11.09.001 Key Key Name 27.11.09.006 Parameter FL1-H Gate G1 27.11.09.016 FL1-H G1 27.11.09.026 FL1-H G1 27.11.09.036 FL1-H G1 FB179 Key 27.11.09.018 27.11.09.028 27.11.09.038 FB118 Key globular head H5 globular head H5 globular head H1 H5 stalk H1 H5 H6 H9 stalk H1 H5 stalk H1 H2 H5 H9 stalk H1 H5 H9 Name 27.11.09.009 27.11.09.019 27.11.09.029 27.11.09.039 HUMABS (Lanzavecchia et al.) FLA3 FLD194 FE17 FE43 FG20 FB179 FB118 Name 27.11.09.008 H5 survivors Vaccinees Soprana Prospettive di ottenere vaccini ricombinanti “universali” contro l’influenza A (stagionale e pandemica) 1. Nel repertorio umano esistono anticorpi neutralizzanti diretti contro parti costanti dell’emagglutinina (poco rappresentati nella risposta, dominata da anticorpi contro la parte globulare variabile. 2. Emagglutinine ricombinanti “headless” inducono risposte neutralizzanti e cross-reattive, mentre emagglutinine “complete” inducono solo risposte contro la parte globulare variabile. 3. Emagglutinine espresse da Poxvirus ricombinanti inducono immunità protettiva nei confronti della influenza A in modelli animali. www.antoniosiccardi.net Antonio Siccardi, 2009 Dance for all (Berlin)